Antibe Therapeutics Inc
TSX:ATE
Antibe Therapeutics Inc
TSX:ATE
Price:
0.295
CAD
Market Closed
Market Cap:
CA$4.7m
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
Antibe Therapeutics Inc
TSX:ATE
|
CA |
|
M
|
Manitex Capital Inc
XTSX:MNX
|
CA |
|
Splitit Ltd
ASX:SPT
|
IL |
|
Hill & Smith Holdings PLC
LSE:HILS
|
UK |
|
scPharmaceuticals Inc
NASDAQ:SCPH
|
US |
|
K
|
Ktbst Mixed Freehold and Leasehold Real Estate Investment Trust
SET:KTBSTMR
|
TH |
|
Recce Pharmaceuticals Ltd
ASX:RCE
|
AU |
|
W
|
Wal Mart de Mexico SAB de CV
SWB:4GNB
|
MX |
|
Is Finansal Kiralama AS
IST:ISFIN.E
|
TR |
|
T
|
Theon International Plc
AEX:THEON
|
CY |
|
C
|
Cemtas Celik Makina Sanayi ve Ticaret AS
IST:CEMTS.E
|
TR |
|
Damodar Industries Ltd
NSE:DAMODARIND
|
IN |
|
E
|
EP&T Global Ltd
ASX:EPX
|
AU |
|
Anterix Inc
NASDAQ:ATEX
|
US |
|
Hospital Mater Dei SA
BOVESPA:MATD3
|
BR |
|
Benchmark Metals Inc
XTSX:BNCH
|
CA |
|
Ocean One Holding Ltd
HKEX:8476
|
HK |
|
H
|
Hutchison Telecommunications (Australia) Ltd
ASX:HTA
|
AU |
|
S
|
San Miguel Corp
XPHS:SMC
|
PH |
|
Servcorp Ltd
ASX:SRV
|
AU |
Multiples-Based Value
There is not enough data to reliably calculate the multiples-based value of ATE.
Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
ATE
Multiples-Based Value
Base Case
Not Available
Multiples Across Competitors
ATE Competitors Multiples
Antibe Therapeutics Inc Competitors
Antibe Therapeutics Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| CA |
|
Antibe Therapeutics Inc
TSX:ATE
|
4.7m CAD | 0 | -0.3 | 1.2 | 1.2 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
829.8B USD | 12.7 | 40.2 | 27.2 | 29 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
579B USD | 6.1 | 21.6 | 15 | 18.4 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 4 | 19.3 | 11.5 | 12.9 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
296B USD | 4.6 | 16.2 | 10 | 12.2 | |
| CH |
|
Novartis AG
SIX:NOVN
|
229.3B CHF | 5.2 | 21.1 | 13 | 16.8 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
214.5B GBP | 5.1 | 29.1 | 16.1 | 22.7 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
237.1B USD | 102.3 | -81.1 | 375.3 | 941.3 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1T DKK | 3.3 | 9.8 | 7.3 | 8.6 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
153.7B USD | 2.5 | 19.8 | 7.6 | 10.2 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
117.8B USD | 2.4 | 16.7 | 7.1 | 8.7 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
